Overview

Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer

Status:
Active, not recruiting

Trial end date:
2022-09-13

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether AZD0156 is safe, what is the best dose to give, and how it is processed by the body when given alone or in combination with other agents. The study will also collect some initial information about how effective it is.

Phase:

Phase 1

Details

Lead Sponsor:

AstraZeneca

Collaborators:

INC Research
Syneos Health

Treatments:

Antineoplastic Agents
AZD0156
Fluorouracil
Folic Acid
Irinotecan
Leucovorin
Levoleucovorin
Olaparib